Abstract Number: 1393 • 2012 ACR/ARHP Annual Meeting
Predictors of Panniculitis in Systemic Lupus Erythematosus
Background/Purpose: Panniculitis is a rare, but devastating manifestation of SLE. We examined associates of panniculitis in a large SLE cohort. Methods: 52 out of 2,149…Abstract Number: 663 • 2012 ACR/ARHP Annual Meeting
The Clinical Significance and Expression of P2X7 Purinergic Receptor in Peripheral Blood from Patients with New-Oneset Systemic Lupus Erythematosus
Background/Purpose: P2X7 purinergic receptor (P2X7R) is encoded by a gene within the human SLE locus SLEB4. Extracellular adenosine triphosphate (ATP) regulates inflammatory cells by activation…Abstract Number: 1395 • 2012 ACR/ARHP Annual Meeting
The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Background/Purpose: SLE is a chronic autoimmune disease with variable manifestations. New developments in the understanding and treatment of SLE mandated closer monitoring of the disease…Abstract Number: 633 • 2012 ACR/ARHP Annual Meeting
Missed Work Days in Systemic Lupus Erythematosus
Background/Purpose: Indirect costs are part of the medical and financial burden of SLE. These costs are easy to undervalue because a significant portion of this…Abstract Number: 2620 • 2012 ACR/ARHP Annual Meeting
Randomized, Double-Blind, Placebo-Controlled Studies of P140 Peptide in Mannitol (Lupuzor) and Trehalose (Forigerimod) in Patients with SLE
Background/Purpose: Advances in the understanding of autoimmune diseases pathogenesis have led to the development of peptide-based therapies that aim to potentially reinstate tolerance to self…Abstract Number: 984 • 2012 ACR/ARHP Annual Meeting
Association of Elevated C5a Levels, but Not the Presence of Anti-Cfh IgG Autoantibodies, with the Deletion of CFHR3 and CFHR1 in SLE
Background/Purpose: We previously reported association of the deletion of complement regulator factor H related CFHR3 and CFHR1 genes (CFHR3-1Δ), rather than CFH exonic SNPs, with…Abstract Number: 639 • 2012 ACR/ARHP Annual Meeting
Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
Background/Purpose: Epratuzumab, a monoclonal antibody targeting CD22, is in development for the treatment of systemic lupus erythematosus (SLE). Two randomized, double-blind trials (ALLEVIATE 1 and…Abstract Number: 2283 • 2012 ACR/ARHP Annual Meeting
Preferential Association of Complement Receptor 2 Variants with Anti-dsDNA Autoantibodies in Systemic Lupus Erythematosus
Background/Purpose: Complement receptor 2 (CR2/CD21) is primarily expressed on B cells and follicular dendritic cells (FDC) and is required for normal humoral immune responses. We…Abstract Number: 992 • 2012 ACR/ARHP Annual Meeting
Functional Genomics of the Human ITGAM Locus
Background/Purpose: ITGAM encodes CD11b, the αM subunit of the Mac-1 -αMβ2 integrin. Mac-1 has many functions on leukocytes including its role as an adhesion molecule…Abstract Number: 613 • 2012 ACR/ARHP Annual Meeting
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Background/Purpose: Syndecan-1(SDC1), a transmemebrane heparan-sulfate glycoprotein, is predominantly expressed by plasma cells and is a receptor for a proliferation-inducing ligand (APRIL). SDC-1 is readily shed…Abstract Number: 2245 • 2012 ACR/ARHP Annual Meeting
Vitamin D Deficiency Is Associated with, but Does Not Predict, Change in hsCRP in Systemic Lupus Erythematosus (SLE)
Background/Purpose: In the general population the cardioprotective effects of vitamin D are thought to be due to modulation of inflammatory cytokines. However, the effects of…Abstract Number: 934 • 2012 ACR/ARHP Annual Meeting
Direct Medical Cost Associated with Organ System Involvement in a Commercially Insured Population with Systemic Lupus Erythematosus in the United States
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs including the heart, lungs, kidneys, as well as the joints and…Abstract Number: 619 • 2012 ACR/ARHP Annual Meeting
Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Background/Purpose: Serum levels of chemokines have been previously used as downstream markers of the interferon (IFN) pathway in SLE. CXCL2 (GROB) and CXCL10 (IP-10) have…Abstract Number: 2247 • 2012 ACR/ARHP Annual Meeting
The First Report of Desensitization to Trimethoprim/Sulfamethoxazole in Patients with Systemic Lupus Eryhtematosus
Background/Purpose: Trimethoprin-sulfamethoxazole (TMP/SMX) is the most effective and widely used prophylactic medication in immunocompromised patients. Some diseases are well-known to cause allergic reactions including human…Abstract Number: 935 • 2012 ACR/ARHP Annual Meeting
Primary Care Preventive Services in Patients with Systemic Lupus Erythematosus Compared to Others in Their Community
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic illness frequently complicated by infections, cardiovascular disease (CVD) and cancer. Primary care preventive services (PCS) are recommended…